Hartmann D, Hussain Y, Güzelhan C, Odink J
Pharma Clinical Research. F. Hoffmann-La Roche Ltd. Basel, Switzerland.
Br J Clin Pharmacol. 1993 Sep;36(3):266-70. doi: 10.1111/j.1365-2125.1993.tb04228.x.
Orlistat (O) is a potent and selective inhibitor of gastrointestinal lipases. The effect on dietary fat absorption following dosing of O at different times relative to meals was investigated in a placebo (P) controlled study in 24 hospitalized healthy males. After a 5-day run-in, to accustom the subjects to a diet of 2400 kcal and 77 g fat per day and to establish baseline faecal fat excretion, subjects received, in four parallel groups of 6. over 8 days three times daily doses of 80 mg O.P.P (group A) or P. 80 mg O.P (group B) or P.P. 80 mg O (group C) or P.P.P (group D) at mid-meal. 1 h and 2 h after mid-meal respectively. Faeces were collected to measure total fat excretion. The mean (s.d.) of faecal fat in percent of dietary fat, after deduction of pre-treatment faecal fat, was (%) 32.8 (8.1), 34.0 (8.8), 26.9 (4.0) and -1.4 (1.7) in groups A. B. C and D respectively. It was concluded that, within the time period investigated, the pharmacological effect of O is not critically dependent on the time of dosing relative to meals.
奥利司他(O)是一种强效且具有选择性的胃肠道脂肪酶抑制剂。在一项针对24名住院健康男性的安慰剂(P)对照研究中,研究了在相对于进餐的不同时间给予O后对膳食脂肪吸收的影响。经过5天的导入期,为使受试者适应每天2400千卡热量和77克脂肪的饮食,并建立基线粪便脂肪排泄量,受试者被分为四组,每组6人,在8天内每天三次分别于餐中、餐后1小时和餐后2小时给予80毫克O、P、P(A组)或P、80毫克O、P(B组)或P、P、80毫克O(C组)或P、P、P(D组)。收集粪便以测量总脂肪排泄量。扣除治疗前粪便脂肪后,A、B、C和D组粪便脂肪占膳食脂肪的百分比的平均值(标准差)分别为(%)32.8(8.1)、34.0(8.8)、26.9(4.0)和 -1.4(1.7)。得出的结论是,在所研究的时间段内,O的药理作用并不严格依赖于相对于进餐的给药时间。